Shelly and Wayne chat with Steve Grossman, President of HPS Group and author of “FDA Matters: The Grossman FDA report,” and Anthony Brogno, Director of Clinical Operations at Lindus Health. You’ll hear their thoughts on how drug development, drug approvals, and clinical trials could be evolving under the new administration’s FDA; priorities in clinical trails for the new FDA Commissioner; the intersection of budget and the FDA’s use of artificial intelligence in its review systems; and much more.

In our headlines segment, Shelly and Wayne delve into these major developments:

Pharma: FDA Holds Virtual Public Workshop on Cell Therapies and Tissue-Based Products

Devices: FDA Issues the Center for Devices and Radiological Health (CDRH) 2024 Annual Report

Food: FDA Publishes New Food Contamination Prevention Strategy

Cosmetics: FDA Plan on Banning Certain Hair-Straightening Chemicals in Limbo

In our Resource Links segment, we listed key documents in our four core areas. To view these links, subscribe, or find out more information about our podcast, visit FDAWatch.net.

Want to be a sponsor, marketing partner, or guest, or provide feedback on the podcast? Email us at [email protected].

Music by Dvir Silver from Pixabay.